Lupin Share Price: Pharma giant ne Europe mein eye care business kharida! Deal size **€190 Million**!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Lupin Share Price: Pharma giant ne Europe mein eye care business kharida! Deal size **€190 Million**!
Overview

Arre suno, Lupin ne Europe mein aankhon ke business waali company VISUfarma ko kharid liya hai! Deal hai **€190 Million** ki. Isse unka specialty business aur Europe mein jo presence hai, woh aur strong ho jayega. Ye deal unke portfolio mein **60 se zyada** branded products jod degi, jo dry eye aur glaucoma jaise issues ke liye hain.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Arey, toh yeh jo acquisition hui hai na, yeh Lupin ke liye Europe mein eye care ke space mein ek game-changer sabit ho sakti hai. VISUfarma ke paas jo alag-alag products ka range hai, woh Lupin ke specialty portfolio ko aur zabardast bana dega. Yeh deal 1st April 2026 se effective hone wali hai aur Lupin isko apni existing cash reserves se manage kar rahi hai. Company ko umeed hai ki isse unki sales aur profit margins mein turant faayda hoga.

Waise, Lupin ka stock ₹2,254.20 pe trade kar raha tha jab yeh news aayi, thoda 1.04% neeche tha. Lekin, agar pichhle 3 saal ka record dekho toh stock ne 247.13% returns diye hain! Europe ka eye care market bhi mast hai, USD 12.4 billion ka toh abhi hai aur 2030 tak USD 18.9 billion tak pahunch jayega, matlab 7.3% ka annual growth rate. Europe mein log bhi badh rahe hain aur diabetes ke karan aankhon ki bimariyan bhi zyada ho rahi hain, toh demand toh hai hi. VISUfarma, jo 2016 mein bani thi, usne €54 Million ka revenue estimate kiya hai 2025 ke liye. Lupin jaisi ₹1.03 lakh crore market cap waali company ke liye yeh ek accha expansion hai.

Lekin game itna bhi aasan nahi hai. Lupin ko Europe mein bade players jaise Novartis, Roche, Alcon, Johnson & Johnson se compete karna padega. Aur haan, Lupin ne pehle bhi kuch regulatory hurdles face kiye hain, jaise FDA ki taraf se issues. Isliye VISUfarma ko integrate karna, unke operations ko match karna aur Europe ke complex rules ko follow karna ek challenge hoga.

Filhaal, analysts positive hain. Unka kehna hai ki Lupin 'Moderate Buy' hai aur price targets ₹2,331.75 se ₹2,472.68 tak ja sakte hain, matlab 5-6% ka upside possible hai. Ye acquisition unke specialty business ko strong karega aur market growth bhi support karegi. Bas integration sahi se ho jaye aur competition mein tikayen, toh aage ki performance achhi ho sakti hai.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.